https://www.live-feeds.com/feed/germany-s-merck-buys-silence-therapeutics-in-1-3-billion-rna-drug-dealContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/germany-s-merck-buys-silence-therapeutics-in-1-3-billion-rna-drug-dealhttps://www.live-feeds.com/feed/germany-s-merck-buys-silence-therapeutics-in-1-3-billion-rna-drug-deal#u150095Fri, 23 Oct 2026 14:32:26 +0000German drugmaker Merck KGaA has agreed to acquire British biotechnology company Silence Therapeutics in an all-cash deal valued at approximately $1.3 billion, with an enterprise value of $1.1 billion. Under the agreement, Merck will pay $20 per American depositary share, representing a 130% premium to the stock's last close. The transaction aims to expand Merck's gene-silencing drug capabilities and precision medicines pipeline following Silence Therapeutics' phase 2 blood cancer win. US-listed shares of Silence more than doubled in morning trading, soaring 125%. The deal is sch